Trials / Completed
CompletedNCT00220129
Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With/Without Surgery for Squamous Cell Carcinoma of the Oesophagus
Neoadjuvant Epirubicin, Cisplatin and Capecitabine (Xeloda) [ECX] Followed by Definitive Chemoradiation With or Without Surgery for Patients With Newly Diagnosed Localized Squamous Cell Carcinoma of the Oesophagus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Royal Marsden NHS Foundation Trust · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to investigate the efficacy and safety of epirubicin, cisplatin and capecitabine (ECX) as neoadjuvant therapy prior to radical chemoradiotherapy using capecitabine and cisplatin as radio-sensitisers in patients with newly diagnosed localized squamous cell carcinoma of the oesophagus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epirubicin, Cisplatin, Capecitabine | |
| PROCEDURE | Surgical Resection |
Timeline
- Start date
- 2002-11-01
- First posted
- 2005-09-22
- Last updated
- 2009-12-16
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00220129. Inclusion in this directory is not an endorsement.